Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer
Open Access
- 1 December 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 4 (4) , 1-10
Abstract
Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients with type II DM and CRC who are also treated with metformin. We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18%) with type II DM; we censored the data of 28 patients because their antidiabetic medications were unknown. We then categorized these 321 patients into two groups: 192 patients treated with metformin (group A) and 129 patients treated with other antidiabetic medications (group B). Group A patients had significantly longer overall survival (89 months; 95% CI, 66 to 112 months) and progression-free survival (47 months; 95% CI, 15 to 79 months) than group B patients (overall survival: 36 months; 95% CI, 24 to 48 months; P ≤ .001; progression-free survival: 21 months; 95% CI, 13 to 29 months; P = .016). After adjustment for age, sex, body mass index, aspirin use, anticholesterol treatment, and CRC stage, group A patients had a 40% reduction in mortality (hazard ratio, 0.58; 95% CI, 0.4% to 0.85%; P = .005). Our results support findings from other populations that patients with diabetes and CRC who are also treated with metformin have better outcomes than those treated with other antidiabetic medications.Keywords
This publication has 38 references indexed in Scilit:
- The effect of metformin and thiazolidinedione use on lung cancer in diabeticsBMC Cancer, 2012
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic CancerClinical Cancer Research, 2012
- Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancerBritish Journal of Cancer, 2012
- Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell TypesCancer Research, 2011
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 2011
- Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancerBritish Journal of Cancer, 2010
- Insulin resistance and hyperinsulinaemia in the development and progression of cancerClinical Science, 2009
- p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal CompartmentCold Spring Harbor Perspectives in Biology, 2009
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong RemissionCancer Research, 2009
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009